

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 3364.31US08

Hinz

Confirmation No.: 5651

Application No.: 10/715,912

Examiner: Lamm, M.

Filed: November 18, 2003

Group Art Unit: 1616

For: COMPREHENSIVE PHARMACOLOGIC THERAPY FOR TREATMENT OF
OBESITY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56, and in addition to information disclosed in Applicants' Information Disclosure Statement filed April 8, 2004 and Supplemental Information Disclosure Statements filed June 6, 2005, November 7, 2005, and February 8, 2006, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The listing of a reference herein is not an admission that the reference is prior art or that the reference is material to patentability.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance.

03/30/2006 HBUJEA1 00000031 10715912


01 FC:1806 180.00 DP

Application No. 10/715,912

Attached is a check in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p). Please credit or debit Deposit Account No. 16-0631 as needed to ensure consideration of the disclosed information.

This application was filed after June 30, 2003; therefore copies of cited U.S. patents and U.S. published applications are not included.

Respectfully submitted,



Paul B. Savereide
Registration No. 36,914


Customer No. 24113
Patterson, Thunte, Skaar & Christensen, P.A.
4800 IDS Center
80 South 8th Street
Minneapolis, Minnesota 55402-2100
Telephone: (612) 252-1550

Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 28, 2006
Date of Deposit


Paul B. Savereide

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/715,912
Filing Date	November 18, 2003
First Named Inventor	Hinz
Art Unit	1616
Examiner Name	Lamm, M.
Attorney Docket Number	3364.31US08

Sheet

1

of

5

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
		US-4,397,866	08-09-1983	Wurtman
		US-5,650,438	07-22-1997	Meier et al.
		US-2001/0002269	05-31-2001	Zhao
		US-6,261,589	07-17-2001	Pearson et al.
		US-2001/0008641	07-19-2001	Krotzer
		US-2001/0008884	07-19-2001	Worsley
		US-2001/0020007	09-06-2001	Wiss
		US-2002/0040054	04-04-2002	Hinz
		US-6,403,657	06-11-2002	Hinz
		US-2002/0147206	10-10-2002	Howard, Jr.
		US-2002/0187958	12-12-2002	Horrobin et al.
		US-2003/0181509	09-25-2003	Hinz
		US-6,660,777	12-09-2003	Hinz
		US-2004/0071681	04-15-2004	Muller
		US-2004/0077556	04-22-2004	Chinery
		US-2004/0081678	04-29-2004	Cincotta
		US-2004/0101575	05-27-2004	Hinz

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
		JP 410067663	03-10-1998	Nickolson	
		WO 01/26642	04-19-2001	Bechthold et al.	

EXAMINER
SIGNATUREDATE
CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616
				Examiner Name	Lamm, M.
Sheet	2	of	5	Attorney Docket Number	3364.31US08
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code ² (if known)			
		US-2004/0116351	06-17-2004	Halevic-Goldman	
		US-2004/0151771	08-05-2004	Gin et al.	
		US-2004/0229285	11-18-2004	Hinz	
		US-2004/0247669	12-09-2004	Gin et al.	
		US-2005/0065190	03-24-2005	Hinz	
		US-2005/0233008	10-20-2005	Hinz	
		US-2005/0233014	10-20-2005	Lee et al.	
		US-2005/0287226	12-29-2005	Sisco et al.	
		US-09/523,114	03-10-2000	Hinz	
		US-11/353,644	02-14-2006	Hinz	
		US-11/353,643	02-14-2006	Hinz	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616
				Examiner Name	Lamm, M.
Sheet	3	of	5	Attorney Docket Number	3364.31US08
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		AGÜNDEZ ET AL, "Modulation of CyP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine", <u>Pharmacogenetics</u> , 8:251-258 (1998).			
		ANDREWS ET AL, "The Effects of 5-hydroxytryptophan and 5-hydroxytryptamine on Dopamine Synthesis and Release in Rat Brain Striatal Synaptosomes", <u>Journal of Neurochemistry</u> , 30:465-470 (1978).			
		AVARELLO, "Serotonin Syndrome: a reported case", <u>Neuro Sci</u> , 23:S55-S56 (2002).			
		BARTHOLOME ET AL., "L-dopa and 5-hydroxytryptophan Therapy in Phenylalanine-Hydroxylase Activity", <u>The Lancet</u> 2(Nov. 22): 1042-1043 (1975).			
		BOUYER ET AL., "Modification of Spontaneous ECoG and Behavior in Cat by Monoamine Precursors", <u>Psychopharmacology</u> , 65:49-54 (1979).			
		COPPEN ET AL. "Levodopa and L-tryptophan Therapy in Parkinsonism", <u>The Lancet</u> , March 25, (1972).			
		DUNNER ET AL., "Affective Disorder: Studeis with Amine Precursors", <u>Am J. Psychiatry</u> , 132(2):180-183 (1975).			
		GELENBERG ET AL. "Tyrosine for the treatment of depression", <u>Nutr. Health</u> , 3(3):163-73 (1984).			
		HURLEY ET AL., "Pyrrolo[1,4]benzodiazepine Antibiotics. Biosynthesis of the Antitumr Antibiotic 11-Demethyltomaymycin and its Biologically Inactive metabolyty Oxotomaymycin to Streptomyces achromogene, <u>Biochemistry</u> , 15(17):3760-3769 (1976).			
		KRAMARCY ET AL, "Effects of Drug-Inducted Changes in Brian Monoamines on Aggression and Motor Behavior in Mice", <u>European Journal of Pharmacology</u> , 99:141-151 (1984).			
EXAMINER SIGNATURE				DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616
Examiner Name				Lamm, M.	
Sheet	4	of	5	Attorney Docket Number 3364.31US08	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		LI KAM WA ET AL., "Renal metabolism and effects of the glutamyl derivates of L-dopa and 5-dihydroxytryptophan in man", <u>Clinical Science</u> , 91:177-185 (1996).			
		LINDSTRÖM ET AL., "Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan", <u>Molecular and Cellular Endocrinology</u> , 48:121-126 (1986).			
		LINDSTRÖM, "Aromatic-L-Amino-Acid Decarboxylase Activity in Mouse Pancreatic Islets", <u>Biochimica et Biophysica Acta</u> , 884: 276-281 (1986).			
		MALONE ET AL., "Treatment (Rx) of 76 Pateitns with Primary Fibromyalgia (1° FM) with Combined Dopaminergic and Serotonergic Drugs", <u>Arthritis & Rheumatism</u> , 39:S92 (1996) (Abstract).			
		MATHIAU ET AL, "Absence of Serotonergic Innervation from Raphe Nuclie in Rat Cerebral Blood Bessesl – II. Lack of Trypthophan Hydroxylase Activity <i>In Vitro</i> " <u>Neuroscience</u> , 52(3): 657-665 (1993).			
		MEYERS, "Use of Neurotranmitter Precursors for Treatment of Depression", <u>Alternative Medicine Review</u> , 5(1):64-71 (2000).			
		NIEDENS ET AL, "First fungal aromatic L-amino acid decarboxylase from a paclitaxel-producing <i>Penicillium raistrickii</i> ", <u>Mycologia</u> , 91(4):61-26 (1999) (Abstract).			
		RABEY ET AL., "L-tryptophan Administration in L-Dopa-Induced Hallucinations in Elderly Parkinsonian Patients" <u>Gerontology</u> , 23:438-444 (1977).			
EXAMINER SIGNATURE				DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616
				Examiner Name	Lamm, M.
Sheet	5	of	5	Attorney Docket Number 3364.31US08	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		SAWAKI ET AL., "Some correlations between Procaine-Induces Convulsions and Monamines in the Spinal Cord of Rats", <u>Japan, J. Pharmacol</u> , 51:369-376 (1989).			
		SCHLOSBERG ET AL., "Effects of L-Dopa and L-5-Hydroxytryptophan on Locomotor Activity of the Rat after Selective or combined destruction of Central Catecholamine and Serotonin Neurons", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 211(2):296-304 (1979).			
		SHINTAKU ET AL., "Diagnosis and treatment of 6-pyruvoyl-tetrahydropterin synthase deficiency", <u>Brain & Development</u> , 22:S118-S121 (2000).			
		STERNBERG ET AL, "Development of Scleroderma-like Illness during Therapy with L-5-hydroxytryptophan and Carbidopa", <u>The New England Journal of Medicine</u> , 303(14):782-787 (1980).			
		TANAKA ET AL., "Hyperphenylalaninemia Due to Impaired Dihydrobiopterin Biosynthesis", <u>Eur. J. Pediatr</u> , 136:275-280 (1981).			
		THURMOND ET AL, "Effects of Dietary Tyrosine, Phenylalanine, and Tryptophan on Aggression in Mice", <u>Pharmacology Biochemistry & Behavior</u> , 6:475-478 (1977).			
		TRULSON ET AL., "Behavioral Effects of Serotonergic and Dopaminergic Drugs in Cats Following Chronic Amphetamine Administration", <u>European Journal of Pharmacology</u> , 99:313-324 (1984).			
		WEITBRECHT AND ET AL., "Der Einfluss von L-Tryptophan auf die L-Dopa-Resorption", <u>Dtsch Med Wochenschr</u> , 101(1): 20-22 (1976).			
		Dave Peterson Affidavit (04/11/2005).			
EXAMINER SIGNATURE				DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					